Latest California Healthline Stories
FDA Weighs Approval of a Lucrative Alzheimer’s Drug, but Benefits Are Iffy
The agency is to decide by June 7 whether to greenlight Biogen’s drug aducanumab, despite a near-unanimous rejection of the product by an FDA advisory committee of outside experts in November. Some scientists at the agency have endorsed the drug, though.
KHN’s ‘What the Health?’: Drug Price Effort Hits a Snag
Democratic leaders in Congress have vowed to pass legislation to address high prescription drug prices this year, but some moderates in their own party appear to be balking. Meanwhile, younger teens are now eligible for a covid-19 vaccine and the Biden administration reinstated anti-discrimination policy for LGBTQ people in health care. Joanne Kenen of Politico, Sarah Karlin-Smith of the Pink Sheet and Rachel Cohrs of Stat join KHN’s Julie Rovner to discuss these issues and more.
KHN’s ‘What the Health?’: Sharing Vaccines With the World
The Biden administration is bucking the drug industry and backing a waiver of covid-19 vaccine patent protections to help the rest of the world vaccinate its populations. Here at home, the Food and Drug Administration wants to ban menthol flavorings for cigarettes, setting off a fight with the tobacco industry. Alice Miranda Ollstein of Politico, Tami Luhby of CNN and Kimberly Leonard of Business Insider join KHN’s Julie Rovner to discuss these issues and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.
Detecting Rare Blood Clots Was a Win, But US Vaccine Safety System Still Has Gaps
With some 100 million Americans fully vaccinated, the U.S. is relying on a patchwork network of vaccine monitoring systems that lack the breadth and depth of large, population-based programs, experts said.
KHN’s ‘What the Health?’: Pause and Effect on Covid Vaccines
Podcast panelists discuss a range of health policy developments, from the latest in the covid vaccination effort to the HHS budget, among other things.
FDA Seeks a New Way to Review Old Drugs Without Causing Prices to Soar
A misguided federal program called the Unapproved Drugs Initiative, which put the FDA’s stamp of approval on old drugs, led to higher prices. It’s scrapped. So now what?
A Year Into Pandemic, Federal Officials Move to Better Protect Front-Line Workers
Changes would allow N95 sales for industries other than healthcare and signal an end to the hospital practice of reusing the masks considered essential for worker safety.
Analysis: How the US Invested in the War on Terrorism at the Cost of Public Health
After 9/11, as our defenses against international and bioterrorism hardened, our defenses against infectious diseases shrank. By the time a deadly virus arrived on our shores last year, nearly two-thirds of Americans were living in counties that spend more than twice as much on policing as they spend on public health.
Scientists Seek Covid Treatment Answers in Cheap, Older Drugs
Philanthropies are funding studies of cheap, existing medications like the antidepressant fluvoxamine as covid treatments. But early hype about hydroxychloroquine and other repurposed drugs leaves researchers leery of hasty conclusions.
Medicamentos ya conocidos, y baratos, podrían ser clave para tratar covid
Hay medicamentos aprobados hace años que podrían investigarse en profundidad para tratar covid. Pero no hay interés porque no generarían grandes ganancias.